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ABSTRACT  The  epidermal  growth  factor  (EGF) receptor  mediates  the  induction  of a trans- 
formed  phenotype  in  normal  rat kidney  (NRK)  cells  by transforming  growth  factors  (TGFs). 
The ability of EGF and its analogue TGF-a to induce the transformed  phenotype in NRK cells 
is greatly  potentiated  by TGF-~, a  polypeptide  that  does  not  interact  directly  with  binding 
sites  for  EGF or TGF-a.  Our  evidence  indicates  that TGF-~ purified  from  retrovirally  trans- 
formed  rat  embryo  cells  and  human  platelets  induces  a rapid  (tl/2 =  0.3  h) decrease  in  the 
binding of EGF and TGF-a to high-affinity  cell surface  receptors in NRK cells.  No change due 
to TGF-~ was observed  in the binding of EGF or TGF-a to lower affinity  sites also present in 
NRK cells. The effect of TGF-~ on EGF/TGF-a  receptors was observed at concentrations (0.5- 
20 pM) similar  to those at which  TGF-~ is active  in  promoting  proliferation  of  NRK  cells  in 
monolayer culture and  semisolid  medium.  Affinity  labeling of NRK cells  and  membranes  by 
cross-linking with receptor-bound  1251-TGF-a and 12SI-EGF indicated that both factors  interact 
with  a  common  170-kD  receptor  structure.  Treatment  of  cells  with  TGF-~  decreased  the 
intensity  of  affinity-labeling  of this  receptor  structure.  These  data  suggest  that  the  170  kD 
high-affinity  receptors for  EGF and TGF-a in  NRK cells  are a target for rapid  modulation  by 
TGF-~. 
Transforming growth factors (TGFs)  ~ are hormonally active 
polypeptides  that  induce  a  transformed  phenotype  when 
added  to  normal  cells  (1).  The  transformed  phenotype  in 
normal rat kidney (NRK) cells,  a  known target cell line for 
TGFs (1), is induced by the synergistic interaction of at least 
two types of TGFs (2,  3).  The  first type, or TGF-a, is an 
analogue of epidermal growth factor (EGF) and is released by 
various neoplastic cell lines (1, 3, 4,  5). EGF and TGF-a are 
6-kD  polypeptides  that  exhibit  significant  amino  acid  se- 
quence homology (3, 5, 6), and similar affinity and mode of 
interaction with a common receptor type (6,  7). The second 
type  of TGF,  or  TGF-t3,  is  a  23-25  kD  molecule  which 
consists of two disulfide-linked 11-12 kD polypeptide chains 
~  Abbreviations  used  in  this  paper."  C18  TGF-0,  TGF-0  purified 
through the C~s reverse phase chromatography step; EGF, epidermal 
growth factor; FeSV-Fre, Synder-Theilen feline sarcoma virus-trans- 
formed rat embryo (cells); NRK, normal rat kidney; TGF, transform- 
ing growth factor. 
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(8-11). TGF-~3 binds to specific receptors that do not recog- 
nize other growth factors ( 12-14). TGF-/3 has no transforming 
action on NRK cells when it acts alone but strongly poten- 
tiates the  transforming action  of TGF-a and  EGF (8-11). 
TGF-~ is found in normal tissues including human platelets, 
human placenta and bovine kidney (8-10), and in retrovirally 
transformed fibroblasts that also produce TGF-a (2, 3). 
The biochemical events elicited by the interaction of TGF- 
/3 with its receptor are unknown at present. However, it has 
been shown that the EGF receptor is a target for regulation 
by agents that complement the proliferative action mediated 
by this receptor type. These include platelet-derived growth 
factor ( 15-18) and phorbol diester tumor promoters ( 19-2 3). 
The modulation of EGF receptors appears to be mediated by 
receptors specific for each of these agents.  These receptor- 
receptor interactions  are  of interest  because they can  help 
identify primary biochemical events involved in the cellular 
actions  mediated  by  growth  factor  receptors.  Thus,  direct 
phosphorylation of certain serine and threonine  residues in 
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receptor for tumor-promoting phorbol  esters,  has been  re- 
cently implied as the biochemical basis for the modulatory 
action of phorbol esters on EGF receptors (22,  24).  Because 
of the biological interaction between TGF-/~ and EGF ana- 
logues, we examined whether the action of TGF-~ on target 
cells also involves modulation of EGF/TGF-t~ receptors. The 
results indicate that TGF-~ from Snyder-Theilen feline sar- 
coma  virus-transformed  rat  embryo  (FeSV-Fre)  cells  and 
human platelets induces a  rapid decrease in the binding of 
EGF and TGF-a to high-affinity receptors in NRK cells. 
MATERIALS  AND  METHODS 
Growth Factors:  TGF-,~  and TGF-B from serum-free  media  condi- 
tioned by FeSV-Fre cells were purified to homogeneity as described previously 
(3,  11). TGF-B from human platelets (9) was purified to homogeneity  by a 
modification  (14) of a  previously described  method (11). No difference has 
been found in molecular structure or biological properties between TGF-B and 
FeSV-Fre cells and human platelets. When indicated, preparations  of TGF-/3 
from FeSV-Fre ceils purified  2,500-fold through the C18 t~Bondapak reverse 
phase chromatography  step (C18 TGF-/3) (11) were used instead of homoge- 
neous preparations of  TGF-B. The purity of  C 18 TGF-B preparations estimated 
by the two bioassays described  below  ranged  between 0.7  and 4%.  Mouse 
submaxillary gland EGF was purified as described (25, 26). TGF-a and EGF 
were labeled with  12~I by the lactoperoxidase-glucose  oxidase method as de- 
scribed previously (7) to a specific activity of 60-70 Ci/g and 80-100  Ci/g, 
respectively. 
Cells and Membrane Preparations:  NRK clone 49F cells (Dr. J. 
E. DeLarco, National Cancer Institute, and American Type Culture Collection, 
CRL  1570) were cultured  in  Dulbecco's  modified  Eagle's medium supple- 
mented with 5% calf serum plus nonessential amino acids (Gibeo Laboratories, 
Grand Island,  NY) or with  10%  calf serum alone,  respectively. Membranes 
from NRK and A431 cells were isolated as described (7). 
Treatment of Cells with TGF-[3:  NRK cells (6 x  104 cells/well) or 
A431 cells (2 x  l04 cells/well) were plated on 35-mm wells and incubated  for 
2 d at 37"C with 2.0 ml of Dulbecco's modified Eagle's medium supplemented 
with  10%  calf  serum.  The sparse  cell monolayers  were  then  washed  with 
Waymouth's medium that contained  0.2% calf serum, and were incubated for 
16-24  h at 37"C in  1.0  ml of this medium before additions  of TGF-~ were 
made. TGF-~ lyophilized in the presence of 5-l0 #g of bovine serum albumin 
(BSA) and reconstituted  in 50 #l of Waymouth's medium was added  to the 
wells to reach the desired final concentrations.  Incubations  continued  for the 
indicated  time  at  37"C and  were  arrested  as described  below  for  binding 
measurements.  In a control  experiment  described below, incubation  of cells 
with TGF-~ at 0-4*(? was done in the presence of binding buffer instead  of 
culture medium. 
Binding Assays:  At the end of the treatment with TGF-#, the medium 
was replaced with ice cold binding buffer ( 125 mM NaCl, 5 mM KCI, 1.2 mM 
MgSO4, 1.2 mM CaCl2, 2 mg/ml of BSA, and 50 mM 4-(2-hydroxyethyl)-l- 
piperazineethanesulfonate,  pH 7.4). Cell monolayers were then incubated at 0- 
4"C with 1.5 ml of binding buffer that contained  125I-TGF-a or t2~I-EGF  at 0.3 
nM final concentration  unless otherwise indicated. Incubations  proceeded for 
3.5 h on a platform oscillating at 2 cycles/s. The medium was then aspirated, 
and the  monolayers  were washed four times with ice cold binding  medium. 
The cell-associated radioactivity  was determined  after  solubilization  of cells 
with two consecutive 0.5-ml  portions of 1%  Triton  X-100 solution  in phos- 
phate-buffered saline (PBS). Nonspecific binding, defined as the binding of J251- 
labeled ligands measured in the presence of 0.2 uM EGF, was routinely 8-15% 
of the total binding  and was subtracted  in all cases. Nonspecific binding was 
not changed by treatment  of cells with TGF-~. Total binding was in all cases 
no more than 0.5% (NRK cells) on 7% (A431 cells) of the input radioactivity 
when ~251-TGF-a or  ~2~I-EGF were present  at  0.3  nM concentration  in  the 
assay. At least 90% of the  ~251-TGF-a and ~251-EGF bound to cells after 3.5 h 
of incubation  at 0-4"C was bound to cell surface receptors as determined by its 
ability to dissociate from the cells after a 3-min  incubation  in the cold with 
acetate-buffered solution at pH 4.5 (27). All binding determinations  were done 
in triplicate.  Cell numbers were determined  with a Coulter  counter (Coulter 
Electronics, Inc., Hialeah, FL) after cells were detached from the culture vessels 
by a short exposure to an isotonic solution  that contained  0.2% trypsin and 
0.02% EDTA. 
Binding of J251-TGF-a and J251-EGF to isolated membranes was determined 
by incubation  of membranes  with ligands in 250 ul of binding medium at 22"C. 
After 60  min,  samples  were placed  on ice, diluted  with 4.0  ml of ice cold 
binding medium, and filtered under negative pressure through 0.2 uM cellulose 
ester microporous filters (Amicon Corp.,  Danvers,  MA). Filters were washed 
twice with 4.0-ml portions of cold medium and counted in a gamma counter. 
Receptor down-regulation experiments were done with A431 cells plated in 
16-mm wells (8  x  l0  a cells/well). 48  h after seeding, the  spent medium was 
removed, and  1.0 ml of fresh medium with the  indicated  concentrations  of 
TGF-#,  TGF-a, or EGF was added.  Incubations  continued  at 37*C for  16 h 
and  were  terminated  by  aspiration  of the  media.  Cells were  prepared  for 
determination  of 125I-TGF-~ binding  as described  in  detail  previously  (7). 
Degradation of TGF-a and EGF during incubation  for 16 h at 37"C with A43 l 
cells in receptor down-regulation  experiments  was significant (8-15%  of hor- 
mone initially added) only at the lowest (0.1-0.5  nM) concentrations  of TGF- 
ct and EGF tested in these experiments, as determined  by a standard  radiore- 
ceptor assay (7). The concentration  values in the experiment shown in Fig. 3 
have been corrected to account  for this limited decrease in the concentrations 
of active hormone during experimentation. 
Receptor Affinity-labeling:  Sparse (2.5 x  104 cells/dish) NRK cell 
monolayers in 150-mm cell culture dishes were incubated in the cold with 15 
ml of binding  medium that  contained  0.33 nM 12~I-TGF-~ or 0.33 nM 1251- 
EGF and unlabeled ligands as indicated. After 3.5 h, this medium was aspirated 
and cells were washed  four times with  ice cold  binding  medium.  25  ml  of 
binding medium plus 320 ~1 of 27 mM disuccinimidyl suberate (Pierce Chem- 
ical Co., Rockford,  IL) in dimethyl sulfoxide (28) were immediately added to 
the cells, and incubation proceeded for 10 min at 0-4"C. Cells were then washed 
twice with 0.25 M sucrose, 10 mM Tris, 1 mM EDTA, pH 7.0, detached from 
the plates by gentle scraping in the presence of this buffer, and centrifuged at 
1,000 g for 5 min. The cell pellet was resuspended with  10 mM Tris,  1 mM 
EDTA, pH 7.0, and solubilized by heating for 3 min at 100*C with  100 ~1 of 
twice-concentrated  electrophoresis sample buffer (29). Insoluble material  was 
removed by centrifugation at 12,000 g for l 0 min. Samples were electrophoresed 
on dodecyl sulfate-polyacrylamide  slab gels as described (29). Electrophoresis 
gels were fixed, stained for protein, dried, and subjected to autoradiography as 
described (30). Molecular weight protein  standards  were carbonic  anhydrase 
(30  kD),  ovalbumin  (45  kD),  BSA  (68  kD),  phosphorylase  b  (94  kD),  B- 
galactosidase (116 kD), and myosin (200 kD). 
Affinity labeling of receptors in isolated membrane preparations  was done 
essentially as described before (31) using 0.20  mM disuccinimidyl  suberate. 
The efficiency of affinity labeling of cells and membranes using this method- 
ology is -7 and 8%, respectively, with 1251-TGF-a, and ~6 and 4%, respectively, 
with ~251-EGF (reference 7; and Massagur, J., unpublished results). 
Bioassays for TGF-/3:  For the assay of [3H]thymidine incorporation 
into DNA, sparse NRK cell monolayers were treated with TGF-~ as described 
above. After 16 h of incubation  with TGF-~, 0.5/zCi of [methyl-3H]thymidine 
(New England  Nuclear,  Boston, MA) in 25  ~1 of Waymouth's medium  was 
added to the cells. 8 h later, wells were washed twice with PBS, and cells were 
solubilized with 0.5 ml of 10 mM Tris, 5 mM EDTA, 0.5% sodium dodecyl 
sulfate, pH 7.4. Lysates were transferred to tubes which contained  1.5 ml of ice 
cold  10%  trichloroacetic  acid. Acid-precipitable  material  was  recovered  by 
filtration  on 0.2  zm microporous cellulose filters. Filters were washed twice 
with 10% trichloroaeetic acid and counted  for radioactivity in the presence of 
4.0 ml Econofluor (New England Nuclear). Control experiments in this labo- 
ratory  have demonstrated  that under the  conditions  of our assay, a  strictly 
linear relationship exists between [3H]thymidine incorporation  into DNA and 
the index of nuclear labeling by [3H]thymidine as determined  by autoradiog- 
raphy of fixed cell monolayers.  Thus, basal incorporation  of [aH]thymidine 
into growth-arrested  NRK-49F  monolayers  is obtained  under conditions  in 
which 2-4% of the nuclei become labeled; maximal  [3H]thymidine incorpora- 
tion  elicited by full serum supplementation  is paralleled by >  95%  nuclear 
labeling; and a fractional stimulation  of [3H]thymidine incorporation  by TGF- 
/~ or other mitogens is closely met by the corresponding increase in the percent 
of labeled nuclei. 
The assays for induction  of anchorage-independent  growth  of NRK cells 
was performed in the presence of 0.3 nM mouse submaxillary EGF, and read 
as previously described (2). 
RESULTS 
TCF-13 Decreases the Binding of TGF-a and EGF 
to Mitogenically Responsive NRK Cells 
Sparse  monolayers of NRK  cells  incubated  for 24  h  in 
medium that contained 0.2%  calf serum were used  in this 
study  because under  these  conditions,  NRK cells  respond 
mitogenically to TGF-/3 as determined by [3H]thymidine in- 
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cell number measurements (reference  11; and Massagu6, J., 
unpublished results). TGF-/3 from FeSV-Fre cells and human 
platelets markedly stimulated the incorporation of [3H]thy- 
midine into acid-precipitable material at concentrations (0.5- 
20  pM)  which  were  also  effective  in  inducing  anchorage- 
independent  proliferation of NRK  cells in  the  presence of 
EGF analogues (Fig.  1 B and reference I 1). We examined the 
ability of TGF-/%treated NRK cells to bind ~2SI-TGF-a and 
~25I-EGF. The binding of ~zSI-TGF-a and  ~2~I-EGF to NRK 
cells was determined at 0-4"C to minimize the contribution 
of post-binding events, i.e., internalization, intracellular deg- 
radation and release, or retention of t2~I-ligand, that rapidly 
occur at higher temperatures (27,  32,  33) and might lead to 
erroneous quantitations of cell surface receptors. Incubation 
at 37"C with TGF-13 from FeSV-Fre cells or human platelets 
decreased the ability of NRK cells to bind ~zSI-TGF-a or ~2~I- 
EGF when radioligands were present in the binding assay at 
a subsaturating (0.3  nM) concentration (Fig.  1A).  The effect 
of TGF-/3  on  TGF-a  and  EGF  binding  to NRK  cells was 
IO0 
m 
o 
8 
o  80 
t~ 
m 
,,,40 
k- 
2o 
~.9  n 
I-.- 
0 
A 
i  i  i  I  I  I  I 
B  ao~ 
40g, 
0 
20 o 
02  05  I  2  5  I0  20  50 
TGF-p CONCENTRATION,  pM 
FIGURE  1  Dose dependent inhibition of TGF-~  and  EGF  binding 
to NRK cells by TGF-/~. (A) Sparse NRK monolayers were incubated 
for 24 h at 37"C with medium that contained 0.2% calf serum. The 
indicated  concentrations  of TGF-/~  from  FeSV-Fre cells  (O,  @)  or 
human platelets (A) were then added to the cells, and incubations 
continued for 2  h  at 37°C.  The medium was then aspirated, and 
monolayers were incubated for 3.5 h at 0-4°C with binding buffer 
that contained 0.3 nM 12SI-TGF-a (@) or 0.3 nM 12SI-EGF (O, A). The 
specifically bound radioactivity was determined after the unbound 
ligands were washed out. Data are the mean (_SD, bars) of triplicate 
determinations and are expressed as the percentage of the specific 
binding of ~2SI-TGF-a (810 cpm/well) or I~SI-EGF (390 cpm/well, O; 
405 cpm/well, A) respectively, to cells not treated with TGF-~. The 
data corresponding to  FeSV-Fre cell-derived TGF-/~  and  platelet- 
derived  TGF-/3  were  obtained  in  separate  experiments.  Five  re- 
peated experiments with TGF-~ from either source yielded similar 
results.  (B)  Induction of [3H]thymidine uptake by various concen- 
trations of TGF-~  from  FeSV-Fre cells  (O)  or  human  platelets (A) 
added to NRK  monolayers cultured as described above, and  pro- 
portion  of  NRK  cells  that  developed  large colonies  in  semisolid 
medium in the presence of 0.3 nM EGF plus the indicated concen- 
trations of TGF-/~  from  FeSV-Fre cells  (@) or human  platelets (a). 
Data are the mean of duplicate determinations. The incorporation 
of  [3H]thymidine  by  NRK  cell  monolayers treated with  10%  calf 
serum was 185-215 pmol/106 cells. 
1510  THE  JOURNAL  OF  CELL  BIOLOGY  •  VOLUME  100,  1985 
I00 
80 
z~6O 
~40 
F- 
I  I  I  j  I 
0  I  2  3  6 
TIME WITH TGF-p, h 
FIGURE  2  Time-dependent inhibition ofl2SI-EGF  binding to NRK 
cells by TGF-~. Sparse NRK monolayers were incubated for 30 h at 
37°C in the presence of 0.2% calf serum-supplemented medium. 
At the indicated times before the end of this incubation,  100 pM 
TGF-~ from human platelets was added to the cell cultures.  After 
this incubation, the medium was aspirated, and  monolayers were 
incubated for 3.5  h at 0-4"C  in the presence of ice cold  binding 
buffer  that  contained  0.3  nM  12SI-EGF. The  specifically  bound 
radioactivity was then determined, and is plotted as the percentage 
of ~2SI-EGF binding (785 cpm/well) to monolayers not treated with 
TGF-/5'. Data are the mean (_SD, bars) of triplicate determinations. 
This experiment was repeated twice with similar results. 
TABLE  I 
Competition of EGF, TGF-a, and TGF-13 with 1251-TGF-a for 
Binding to Isolated Membranes 
Membrane source  Competing ligand  1251-TGF-oL  bound 
NRK cells 
A431 cells 
[moiling protein 
None  5.4 
66 nM TGF-a  1.2 
66 nM EGF  1.6 
66 nM TGF-/~  5.6 
330 nM TGF-/~  5.6 
None  2220 
66 nM TGF-a  140 
66 nM EGF  140 
66 nM TGF-/3  2130 
330 nM TGF-/3  2170 
Membranes were incubated for 60 rain at 22 °C in the presence of 0.25 nM 
'251-TGF-a alone or with the  indicated  concentrations  of TGF-a,  EGF, or 
platelet-derived TGF-B. Total binding was then determined as described  in 
Materials and Methods. Data are the mean of duplicate determinations. 
concentration-dependent  and  was  half-maximal  at  ~0.5-1 
pM  TGF-/3  (Fig.  1A).  This effect was also rapid and time- 
dependent, being half-maximal after -20 min, and was com- 
pleted after -2 h of cell exposure to TGF-/3 (Fig. 2). It persisted 
for at least 6  h after addition of TGF-/3  (Fig. 2). The modu- 
lation of ~251-TGF-a and  125I-EGF binding to NRK cells by 
TGF-~ was temperature-dependent. No effect on ~zSI-TGF-a 
or ~25I-EGF binding was observed in NRK cells exposed to 
TGF-# at 0-4"C instead of 37"C (not shown). 
TGF-/~ did not appear to interact directly with EGF/TGF- 
a  binding sites. Thus, biologically saturating concentrations 
of TGF-~  did  not compete with  125I-TGF-a  for binding to 
membrane preparations from NRK or A431  cells (Table I). 
No detectable decrease in the binding of 50 pM  t25I-TGF-a 
or 50  pM  '25I-EGF  to A431  cells was observed when cells 
were exposed for 2 h at 37"C to concentrations of TGF-~ that 
were active  on  NRK  cells (not shown).  Exposure  of A431 
cells to TGF-a or EGF decreases the number of cell surface 
binding sites for these two ligands in parallel (7). This receptor 
down-regulation phenomenon is a function of the persistent 
occupancy of binding sites by the corresponding ligand (33, 34).  However, biologically active concentrations  of TGF-3 
did not cause down-regulation of EGF/TGF-a receptors in 
A431  ceils under conditions in which TGF-a and EGF did 
(Fig.  3).  These data suggest that the modulation of TGF-~ 
and EGF binding to NRK cells by TGF-3 involves an indirect 
mechanism that is operative in NRK cells but is apparently 
missing in A431  cells. 
TGF-3 Decreases Binding of EGF and TGF-a to 
High-affinity Cell Surface Receptors 
To gain more information on the nature of the change in 
EGF/TGF-a receptors induced by TGF-3 on NRK cells, we 
analyzed the binding of various concentrations of ~2~I-TGF-a 
to control and TGF-3-treated cells. Scatchard analysis of the 
binding of 125I-TGF-a to control NRK monolayers at 0-4"C 
yielded a curvilinear isotherm (Fig.  4).  The curvilinearity of 
Scatchard plots in other hormone receptor systems has been 
explained by either negative cooperativity  among binding sites 
whereby increasing occupancy of receptors by the ligand leads 
to  a  decreasing  affinity,  or  the  simultaneous  presence  of 
binding sites with different affinities for the ligand. However, 
it has been shown (21) that EGF receptors in rat fibroblasts 
are not subject to negative cooperativity. Therefore, the sim- 
plest interpretation for the complex binding of EGF and TGF- 
a  to receptors in NRK cells is the presence of two classes of 
binding sites with high and low affinity for the ligand, respec- 
tively. According to this  interpretation,  control  NRK cells 
exhibit on their surface a small (~6 x  103 sites/cell) population 
of binding sites with high (K~ =  0.2-0.3 nM) affinity for 125I- 
TGF-a,  and  a  larger (~1.8  x  104  sites/cell)  population  of 
binding sites with  low (IG =  2.7-2.9  nM)  affinity for this 
ligand, as estimated graphically from the slope and abscissa 
intercept of the two rectilinear components of the Scatchard 
plot (Fig.  4).  Treatment of NRK cells  for 2  h  at 37"C with 
platelet-derived TGF-3 induced a  marked decrease in high- 
affinity binding of J251-TGF-a to the cells, whereas little or no 
decrease was observed in binding to the low-affinity sites (Fig. 
4).  Similar results were obtained when the experiment was 
repeated with TGF-3 from FeSV-Fre cells (not illustrated). 
Thus,  TGF-3 appears to  affect selectively the  high-affinity 
binding sites for 125I-TGF-a in NRK cells. 
A  170-kD  Receptor Species is the Target for 
Modulation by TGF-3 
We sought to define structurally the EGF/TGF-~ receptor 
species that was the target for modulation by TGF-3 in NRK 
cells.  Intact NRK cells and isolated NRK membranes were 
cross-linked with bound  '2SI-TGF-a and  ]2SI-EGF using di- 
succinimidyl suberate, and were displayed by electrophoresis 
on dodecyl sulfate-polyacrylamide gels and autoradiography 
(Fig.  5).  NRK membrane preparations affinity-labeled with 
~25I-TGF-a or ~25I-EGF exhibited a  lT0-kD labeled compo- 
nent (Fig. 5, lanes a and d) whose labeling could be inhibited 
by an excess native TGF-a or EGF added during incubation 
of membranes with  l:5I-labeled ligands (Fig.  5, lanes b, c, e, 
and f). We identify this  170-kD membrane component as a 
common  receptor  species  for  TGF-a  and  EGF  similar  in 
molecular size and binding properties to EGF/TGF-a recep- 
tors in other cell types (7, 33-36). No other specifically labeled 
components could be identified in cross-linked NRK mem- 
branes even at the relatively high (10 riM) concentrations of 
~25I-TGF-a and ~25i-EGF used in these experiments. At these 
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FIGURE  3  TGF-3  does not down- 
regulate  EGF/TGF-a  receptors  in 
A431  cells.  Sparse monolayers of 
A431 cells were incubated for 16 h 
at 37*C with fresh culture medium 
that contained C18 TGF-3 (A), TGF- 
a  (O), or EGF (0). The concentra- 
tions of TGF-3 present in the assays 
were  estimated  by  two  different 
bioassays of the  partially purified 
C18 TGF-/3 preparation  (see Mate- 
rials and  Methods). At the end of 
this incubation, cell surface-bound 
ligands were dissociated by a brief 
exposure  to medium at acidic pH 
(27), and the specific binding of 1 
determined.  Results are expressed 
as the percentage of 12SI-TGF-o~  binding (23,500 cpm/well) to mon- 
olayers not treated with bioactive peptides.  Data are the average 
of duplicate determinations. 
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FICURE 4  TGF-3  decreases the high-affinity binding of ~251-TGF-a 
to cell surface receptors. Sparse NRK monolayers incubated for 24 
h in medium that contained 0.2% calf serum received 100 pM TGF- 
3 (0) or no additions (O). Incubations continued for 2 h at 37°C. 
This medium was then aspirated, and monolayers were incubated 
at 0-4°C for 3.5 h in the presence of various (0.1-5.0 nM) concen- 
trations of 12SI-TGF-a in  binding buffer. A Scatchard  plot with the 
amount of ligand specifically bound under these conditions plotted 
against the ratio of bound over free ligand is shown. Data are the 
mean (+SD) of triplicate determinations. 
ligand concentrations, various membrane components were 
labeled in addition to the  170-kD species, but none of them 
was sensitive to the presence of an excess of native TGF-a or 
EGF (Fig. 5, lanes a-f). 
A 170-kD EGF/TGF-a receptor species could also be iden- 
tified after electrophoresis and autoradiography of  intact NRK 
cells affinity-labeled with 0.3 nM ~251-TGF-a or 0.3 nM 125I- 
EGF (Fig. 5, lanes g and i). In addition to this 170-kD species, 
NRK cell preparations also exhibited trace amounts of a 140- 
kD component specifically labeled with ~25I-TGF-a and 125I- 
EGF (Fig. 5, lanes g and i; and Fig. 6). This lower M, species 
may have originated  by limited proteolysis of the  affinity- 
labeled 170-kD receptor species during scraping and homog- 
enization of the affinity-labeled cells,  as has been previously 
documented (37,  38).  No other components specifically la- 
beled by ~25I-TGF-a or 125I-EGF could be detected in intact 
NRK cells (Figs. 5 and 6): 
When  intact  NRK cell  monolayers were  affinity-labeled 
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EGF/TGF-a  receptor  species 
in NRK membranes and intact 
cells.  Alilquots  (0.3 mg  of 
membrane  protein)  of  NRK 
membranes suspended in 0.3 
ml  of  binding medium  were 
incubated for 60 min at 230C 
in the presence of 10 nM ~251- 
TGF-~x (lanes a-c)  or  10  nM 
~251-EGF (lanes d-f).  An excess 
(1  pM)  of  unlabeled  TGF-~ 
(lanes b and e) or EGF (lanes c 
and f) was also present in the 
indicated  samples. Monolay- 
ers  of  NRK  cells  were  incu- 
bated for 3.5 h at 0-4°C in the 
presence of 0.33 nM ~251-TGF- 
(lanes g and h) or 0.33  nM 
12SI-EGF (lanes i and j),  alone 
(lanes g and i) or with 100 nM 
EGF (lanes h and j). At the end 
of  incubations,  membranes 
and cells were washed free of 
unbound  ligand  and  cross- 
linked at 0*C  with  bound li- 
gands  using  disuccinimidyl 
suberate as described  in Ma- 
terials and Methods. Electrophoresis of the affinity-labeled samples was performed on a 6-10% polyacrylamide gradient gel (lanes a-f) or 
on a 5-9% polyacrylamide gel (lanes g-j).  Shown are the autoradiograms of the fixed, dried gels. Numbers  indicate the molecular weight 
in kilodaltons and the position of protein standards run on parallel tracks. Arrowheads point at the 170-kD and the 140-kD labeled species. 
FIGURE 6  TGF-fl induces a decrease in the 
labeling of the 140-170 kD EGF/TGF-~ re- 
ceptor in NRK cells. (A) Sparse NRK mono- 
layers  cultured  for  24  h  in  medium  that 
contained 0.2% calf serum received 0.2 ~g[ 
ml  of C18  TGF-/3 (equivalent to  100  pM 
TGF-fl) (lane b) or no additions (lanes a and 
c).  After  2  h  at  37°C,  monolayers were 
washed  with  binding  medium  and  incu- 
bated for 3.5 h at 0-4"C with binding me- 
dium  that  contained  0.3  nM  ~251-TGF-(~ 
alone (lanes a and b) or in the presence of 
0.2  pM  native  EGF  (lane  c).  Monolayers 
were then washed,  cross-linked  to  bound 
ligands, solubilized,  and electrophoresed  on 
a 6-10%  polyacrylamide gradient gel. An 
autoradiogram from the fixed, dried gel is 
shown.  (B) Densitometry of gel  lanes a,  b 
and c, between lane origin and the 68-kD 
position. Arrowheads  point at  specifically 
labeled bands. 
with 0.3 nM ~2~I-TGF-a after preincubation with TGF-fl, the 
intensity of labeling of the  140-170 kD receptor species was 
only about one  half of that  in  control  ceils (Fig.  6).  This 
decrease in labeling is consistent with a lower occupancy of 
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the  170-kD  receptor species in  TGF-fl-treated cells.  These 
data suggest that the  170 kD EGF/TGF-a receptor species is 
the target for modulation of EGF and TGF-a binding to NRK 
cells by TGF-fl. DISCUSSION 
The results reported here indicate that exposure Of NRK cells 
to  biologically  active  concentrations  of TGF-/3  leads  to  a 
change in EGF/TGF-a cell surface receptors. In confirmation 
of previous results (39),  we find that EGF/TGF-a receptors 
in  NRK  cells that  are  mitogenically  responsive to  TGF-/3 
exhibit a  complex ligand binding pattern (Fig.  4).  Complex 
binding of ~25I-EGF  that yields curvilinear Scatchard plots has 
also been observed in other cell types (7,  16, 20, 2 l, 32). The 
simplest interpretation of these binding properties is the pres- 
ence of a  mixed cell surface receptor population minimally 
consisting of two classes of binding sites with high (K~ = 0.2- 
0.3 nM) affinity and low (Kd =  2.7-2.9  nM) affinity for the 
ligand, respectively. According to this model, our data suggest 
that  TGF-/3  induces  a  rapid  (ll/2  ----- 0.3  h)  and  persistent 
inhibition ofligand binding to high-affinity sites on the surface 
of NRK  cells without  significantly altering the  binding  to 
lower affinity sites.  This effect of TGF-/3 is temperature- and 
concentration-dependent. The effect on 125I-TGF-a and ~25I- 
EGF binding to NRK cells was half-maximal at 0.5-1.0 pM 
TGF-/3,  a concentration lower than the concentration (2-10 
pM)  of TGF-/3  required  for  half-maximal  stimulation  of 
[3H]thymidine incorporation into DNA  or anchorage-inde- 
pendent proliferation of NRK cells. The apparent discrepancy 
in the range of TGF-/3 concentrations required for these two 
types of effects is  likely due  to  substantial  degradation  of 
TGF-B during prolonged (l-10 d) incubation with cells in the 
mitogenic activity assays. 
EGF and TGF-a share a common 170-kD receptor type in 
NRK cells as determined by receptor-affinity labeling meth- 
odology (Figs.  5 and 6). The sharing of a common receptor 
species by EGF and TGF-a has been documented in other 
cell types as well (1, 7, 39, 40). The decreased affinity labeling 
of this receptor species in TGF-/3-treated NRK cells as com- 
pared with untreated cells is consistent with it being the target 
for TGF-/3 regulation of TGF-a and EGF binding. 
No  other  receptor  species  for TGF-a or  EGF could  be 
identified in affinity-labeling experiments performed in this 
laboratory with five different NRK cell membrane prepara- 
tions or with intact NRK cells obtained from two different 
sources. Similarly, only 140-170 kD receptor species common 
for EGF and  TGF-a were detected  by affinity labeling of 
membranes from other tissues and  cell types including  rat 
and  human  liver,  rat and  human  placenta,  rat  adipocytes, 
A431  human epitheloid carcinoma, T24 human bladder car- 
cinoma, T85 human osteosarcoma, WI38 human lung fibro- 
blasts, FeSV-Fre cells, and Swiss 3T3 mouse fibroblasts (ref- 
erence 7; and Massagur, J., manuscript submitted for publi- 
cation). The results from ligand binding experiments (Table I 
and reference 7) are also inconsistent with the hypothesis of 
separate receptor types existing for EGF and TGF-a. These 
results are in contrast to the previously reported presence of 
a 60-kD membrane component in NRK cells that can interact 
with "sarcoma growth factor" (partially purified mouse TGF- 
that  also contains  TGF-/3,  see reference 2) but  not  with 
mouse EGF (40).  This difference could be due to the use in 
previous studies of crude preparations of "sarcoma growth 
factor"  derivatized  with  [~25I]iodo N-succinimidyl-3-(4-hy- 
droxyphenyl) propionate and purified by binding and elution 
from A431  cells (40) instead of homogenous preparations of 
chemically and biologically intact  J25I-TGF-a  (7) as used in 
the present studies. The 60-kD labeled component could be 
a minor TGF-/3 receptor species (14) affinity labeled by '251- 
TGF-~3 present  in  the  radiolabeled  sarcoma growth  factor 
preparations. 
The modulation of EGF/TGF-a receptors by TGF-/3 does 
not appear to. result from a direct interaction of this factor 
with EGF or TGF-o~ binding sites for various reasons. First, 
TGF-/3 does not compete with  IzSI-TGF-a (Table I) or ~25I- 
EGF (not shown) for binding to receptors in isolated mem- 
brane preparations. Other studies (12-14) show that 12~I-TGF- 
/3 binds with high affinity to membrane receptors in various 
cell lines including NRK cells,  and binding is competed for 
by TGF-/3 but not by EGF or TGF-a. Furthermore, receptor 
affinity-labeling studies  indicate that  the  receptor for  125I- 
TGF-/3 in  rat  flbroblasts is  a  glycosylated, disulfide-linked 
complex that contains a 280-kD ligand binding subunit, and 
is therefore distinct from EGF/TGF-a receptor structures (14, 
41,  42).  Secondly,  active concentrations  of TGF-/3  do  not 
cause down-regulation of EGF/TGF-a receptors in A431 cells 
under conditions in which mitogenically equivalent concen- 
trations of EGF or TGF-a do. Third, we did not observe any 
decrease in the binding of low concentrations of 125I-TGF-a 
or ~zSI-EGF to A431  cells treated with TGF-/3  under condi- 
tions  in  which  TGF-/3  elicited  a  marked  decrease  in  the 
binding of these  ligands to  NRK  cells.  These observations 
indicate that the effect of TGF-/3 on EGF/TGF-a receptors 
in NRK cells is mediated by a mechanism that may not be 
operative in other cell types (such as A431  cells),  or under 
other cell culture conditions. 
The results reported here are in contrast to the observation 
(43) of a small and transient decrease of EGF binding to NRK 
cells after addition  of TGF-/3,  then  a  two-fold increase  in 
binding at later (6 h) time points. The reason for this discrep- 
ancy is unclear, but it is interesting to note that the different 
effects of  TGF-/3 on EGF binding observed in these two studies 
are  correlated  with  differences in  the  ability  of NRK  cell 
cultures to respond mitogenically to TGF-/3.  Thus, whereas 
other studies (43) were carried out with confluent monolayers 
of NRK cells reported to be mitogenically unresponsive to 
TGF-/3, the results reported here were performed with sparse, 
serum-deprived cultures of NRK cells that respond mitogen- 
ically to TGF-/3.  It is possible that TGF-/3 has a dual action 
on EGF/TGF-a receptors, and that the inhibitory effect of 
TGF-# on EGF/TGF-a binding predominates in situations 
in which cells evolve from a growth-arrested state to a mito- 
genically active one. 
The effect of TGF-/3 on EGF/TGF-a receptors described 
here is similar, and may be related to the modulation of the 
affinity of this receptor type by platelet-derived growth factor 
(14-17),  fibroblast-derived growth  factor  (18),  and  tumor 
promoters including phorbol diterpene esters, certain indole 
alkaloids, and polyacetates (20,  21,  23).  These agents have 
been reported to potentiate or complement the cellular actions 
of EGF analogues, yet they acutely decrease the binding of 
'25I-EGF to  high-affinity  receptors  in  cultured  cells.  It  is 
possible as proposed before (21)  that  potentiation of long- 
term actions of EGF by these agents is a consequence of a 
decreased  degradation  of EGF  in  the  medium  due  to  its 
decreased binding and internalization  by cellular receptors. 
However, the exact significance of these paradoxical obser- 
vations may not be clear until the role and cellular dynamics 
of EGF/TGF-a receptors with high and low apparent affinity 
for the ligand are established. 
The observations reported here may help identify primary 
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effect of TGF-B on  EGF/TGF-a  receptors  may be  accom- 
plished by the induction of  a molecular change in this receptor 
molecule that could convert it into a  lower affinity state or 
target it for rapid removal from the cell surface. In an analo- 
gous  situation,  a  molecular  change  of the  EGF  receptor, 
namely its phosphorylation on discrete sites by protein kinase 
C,  has been  proposed as the  basis  for modulation  of EGF 
receptors  by  phorbol  ester  tumor  promoters  (22,  24,  44). 
Alternatively,  TGF-B may induce  a  redistribution  between 
the cell surface and an intracellular location(s) of preexisting 
EGF/TGF-a  binding sites with  different  affinity for the  li- 
gands. Efforts to address the molecular basis for the modula- 
tion of EGF/TGF-a receptors by TGF-B are underway. 
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